Search

Author/Creator Raskin, P.

1. AMG 151 (ARRY‐403), a novel glucokinase activator, decreases fasting and postprandial glycaemia in patients with type 2 diabetes. Issue 2 (14th December 2015)

Authors:
Katz, L.; Manamley, N.; Snyder, W. J.; Dodds, M.; Agafonova, N.; Sierra‐Johnson, J.; Cruz, M.; Kaur, P.; Mudaliar, S.; Raskin, P.; Kewalramani, R.; Pellacani, A.
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 18:Issue 2(2016)
Page Start:
191
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double‐blind randomized controlled trial (BEGIN: ADD TO GLP‐1 Study). Issue 7 (2nd May 2016)

Authors:
Aroda, V. R.; Bailey, T. S.; Cariou, B.; Kumar, S.; Leiter, L. A.; Raskin, P.; Zacho, J.; Andersen, T. H.; Philis‐Tsimikas, A.
Journal:
Diabetes, obesity & metabolism
Issue:
Volume 18:Issue 7(2016)
Page Start:
663
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗